Immunogenicity of Current and New Therapies for Hemophilia A
Anti-drug antibody (ADA) development is a significant complication in the treatment of several conditions. For decades, the mainstay of hemophilia A treatment was the replacement of deficient coagulation factor VIII (FVIII) to restore hemostasis, control, and prevent bleeding events. Recently, new p...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI AG
2022-07-01
|
| 叢編: | Pharmaceuticals |
| 主題: | |
| 在線閱讀: | https://www.mdpi.com/1424-8247/15/8/911 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|